Biomarkers for Radiation Response Prediction
Biomarkers for radiation response prediction are transforming precision oncology by enabling individualized treatment planning and improved outcome forecasting. This session explores molecular, genetic, proteomic, and imaging-based biomarkers that help predict tumor radiosensitivity and normal tissue toxicity. Advances in genomic profiling, DNA repair pathway analysis, and immune-related markers are refining patient stratification and guiding dose personalization. Radiomic signatures derived from advanced imaging are increasingly integrated with artificial intelligence models to enhance predictive accuracy. Experts will discuss translational research validating biomarker-driven adaptive radiotherapy and risk-based treatment de-escalation strategies. Challenges including data standardization, reproducibility, and global accessibility of molecular testing will also be addressed. By incorporating biomarker insights into routine practice, clinicians can minimize adverse effects while maximizing tumor control. This precision-based approach represents a significant advancement toward biologically guided radiation therapy, improving survival outcomes and supporting more cost-effective, patient-centered cancer care worldwide.